How to buy Evelo Biosciences stock | $7.95

Evelo Biosciences Inc is a biotechnology business based in the US. Evelo Biosciences shares (EVLO) are listed on the NASDAQ and all prices are listed in US Dollars. Evelo Biosciences employs 90 staff and has a market cap (total outstanding shares value) of 0.00.

Evelo Biosciences stock price (NASDAQ: EVLO)

Use our graph to track the performance of EVLO stocks over time.

Evelo Biosciences shares at a glance

• Key figures

Information last updated 2021-10-10.

Latest market close	$7.95
52-week range	$3.82 - $19.93
50-day moving average	$8.41
200-day moving average	$11.06
Wall St. target price	$22.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.22

Buy Evelo Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Evelo Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Evelo Biosciences price performance over time

Historical closes compared with the close of $7.95 from 2021-10-15

1 week (2021-10-08)	15.55%
1 month (2021-09-17)	-4.68%
3 months (2021-07-16)	-29.96%
6 months (2021-04-16)	-31.23%

1 year (2020-10-16)	61.26%
2 years (2019-10-17)	18.83%
3 years (2018-10-17)	9.81
5 years (2016-10-13)	N/A

Evelo Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-49.96%
Return on equity TTM	-167.2%
Profit margin	0%
Book value	$1.16
Market capitalisation	$367.4 million

TTM: trailing 12 months

Shorting Evelo Biosciences shares

There are currently 3.6 million Evelo Biosciences shares held short by investors – that's known as Evelo Biosciences's "short interest". This figure is 12.4% up from 3.2 million last month.

There are a few different ways that this level of interest in shorting Evelo Biosciences shares can be evaluated.

Evelo Biosciences's "short interest ratio" (SIR)

Evelo Biosciences's "short interest ratio" (SIR) is the quantity of Evelo Biosciences shares currently shorted divided by the average quantity of Evelo Biosciences shares traded daily (recently around 186025.33748702). Evelo Biosciences's SIR currently stands at 19.26. In other words for every 100,000 Evelo Biosciences shares traded daily on the market, roughly 19260 shares are currently held short.

However Evelo Biosciences's short interest can also be evaluated against the total number of Evelo Biosciences shares, or, against the total number of tradable Evelo Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Evelo Biosciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Evelo Biosciences shares in existence, roughly 70 shares are currently held short) or 0.1325% of the tradable shares (for every 100,000 tradable Evelo Biosciences shares, roughly 133 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Evelo Biosciences.

Find out more about how you can short Evelo Biosciences stock.

Evelo Biosciences share dividends

We're not expecting Evelo Biosciences to pay a dividend over the next 12 months.

Evelo Biosciences share price volatility

Over the last 12 months, Evelo Biosciences's shares have ranged in value from as little as $3.82 up to $19.928. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evelo Biosciences's is 1.4927. This would suggest that Evelo Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Evelo Biosciences overview

Evelo Biosciences, Inc. , a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Evelo Biosciences is owned by insiders or institutions?
Currently 0.512% of Evelo Biosciences shares are held by insiders and 88.98% by institutions. How many people work for Evelo Biosciences?
Latest data suggests 90 work at Evelo Biosciences. When does the fiscal year end for Evelo Biosciences?
Evelo Biosciences's fiscal year ends in December. Where is Evelo Biosciences based?
Evelo Biosciences's address is: 620 Memorial Drive, Cambridge, MA, United States, 02139 What is Evelo Biosciences's ISIN number?
Evelo Biosciences's international securities identification number is: US2997341035 What is Evelo Biosciences's CUSIP number?
Evelo Biosciences's Committee on Uniform Securities Identification Procedures number is: 299734103